Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Athenex to layoff 92 workers as it closes New York plant

By Brian Buntz | January 3, 2023

AthenexThe biotech Athenex (Nasdaq:ATNX) plans to close a facility in Clarence, New York, by March 17, according to a notice from the New York State Department of Labor. It will cut 92 jobs in the process.

The company also noted it would close its 503B sterile compounding business to focus on cell therapy. In the third quarter of 2022, the unit was responsible for roughly 19% of its product sales.

ATNX shares were up 17.90% to $0.17.

On February 5, 2021, its shares traded at $14.00.

Complete response letter from FDA

One factor driving its share price lower was a complete response letter (CRL) from the FDA in March 2022 for its New Drug Application (NDA) for oral paclitaxel with encequidar to treat metastatic breast cancer.

The company’s oral paclitaxel formulation also recently failed to win regulatory approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for metastatic breast cancer as a result of Chemistry, Manufacturing and Control (CMC) issues.

Athenex CEO Dr. Johnson Lau noted that the company had addressed major concerns about oral paclitaxel’s clinical efficacy and safety. The company believes the CMC issues that prevented MHRA approval are addressable.

Paclitaxel, whose brand name is Abraxane, won FDA approval in 1992 to treat ovarian cancer. An indication followed in 1994 for advanced breast cancer.

The iSPY 2 study

The oral form of the drug was included among the treatment options of the Phase 2 iSPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and Molecular AnaLysis 2, NCT01042379).

The iSPY 2 study provided “an important data set that further characterizes the safety profile of oral paclitaxel, and we plan to amend our metastatic breast cancer NDA with the iSPY 2 safety data this quarter,” Lau said in a news release.

FDA’s complete response letter noted that the oral paclitaxel arm in a clinical trial appeared to be associated with an increased risk of neutropenia-related sequelae compared to those receiving IV paclitaxel.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE